208 related articles for article (PubMed ID: 34397577)
1. Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.
Valikodath NG; Chiang MF; Chan RVP
Curr Opin Ophthalmol; 2021 Sep; 32(5):468-474. PubMed ID: 34397577
[TBL] [Abstract][Full Text] [Related]
2. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
Patel JR; Ranjan SS; Wasserman BN
Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
4. Complications of retinopathy of prematurity treatment.
Barnett JM; Hubbard GB
Curr Opin Ophthalmol; 2021 Sep; 32(5):475-481. PubMed ID: 34231532
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
6. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
7. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
[TBL] [Abstract][Full Text] [Related]
8. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
[TBL] [Abstract][Full Text] [Related]
11. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
12. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
Chawla D; Darlow BA
Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
[TBL] [Abstract][Full Text] [Related]
13. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
Mireskandari K; Collins ME; Tehrani N
Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
[No Abstract] [Full Text] [Related]
15. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
Kong Q; Ming WK; Mi XS
BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
17. Atypical case of retinopathy of prematurity with candle wax-like preretinal deposits and its surprising response to intravitreal antivascular endothelial growth factor.
Shah MS; Padhy SK; Sahu S; Padhi TR
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039342
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological treatment for retinopathy of prematurity].
Stahl A; Agostini H; Jandeck C; Lagrèze W
Ophthalmologe; 2011 Aug; 108(8):777-85; quiz 786-7. PubMed ID: 21853221
[TBL] [Abstract][Full Text] [Related]
19. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
20. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
